Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis

Critical Care

Volumn 13, Issue 5, 2009, Pages

  Lorente, Leonardo ^a   Martín, María M ^b   Labarta, Lorenzo ^c   Díaz, César ^d   Solé Violán, Jordi ^e   Blanquer, José ^f   Orbe, Josune ^g   Rodríguez, José A ^g   Jiménez, Alejandro ^a   Borreguero León, Juan M ^a   Belmonte, Felipe ^b   Medina, Juan C ^b   LLimiñana, Maria C ^c   Ferrer Agüero, José M ^e   Ferreres, José ^f   Mora, María L ^a   Lubillo, Santiago ^b   Sánchez, Manuel ^d   Barrios, Ysamar ^a   Sierra, Antonio ^a   Páramo, José A ^g   more..

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^c HOSPITAL SAN JORGE   (Spain)

^d HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^e HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GELATINASE B; INTERLEUKIN 10; INTERSTITIAL COLLAGENASE; LACTIC ACID; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APACHE; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEPSIS; THROMBOCYTE COUNT; BLOOD; HOSPITALIZATION; MIDDLE AGED; OBSERVATION; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; SPAIN; SURVIVAL;

BIOLOGICAL MARKERS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OBSERVATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SEPSIS; SEVERITY OF ILLNESS INDEX; SPAIN; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77949891826     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8115     Document Type: Article

References (48)

1. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002, 3:207-214. 10.1038/nrm763, 11994741.
2. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993, 4:197-250.
3. Elkington PT, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005, 142:12-20. 10.1111/j.1365-2249.2005.02840.x, 1809491, 16178851.
4. Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 2002, 67:92-98. 10.1023/A:1013908332232, 11841344.
5. Kluft C. The fibrinolytic system and thrombotic tendency. Pathophysiol Haemost Thromb 2003, 33:425-429. 10.1159/000083840, 15692255.
6. Santos-Martínez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res 2008, 121:535-542. 10.1016/j.thromres.2007.06.002, 17681591.
7. Pugin J, Widmer MC, Kossodo S, Liang CM, Preas H, Ln Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999, 20:458-464.
8. Albert J, Radomski A, Soop A, Sollevi A, Frostell C, Radomski MW. Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers. Acta Anaesthesiol Scand 2003, 47:407-410. 10.1034/j.1399-6576.2003.00059.x, 12694137.
9. Torii K, Iida K, Miyazaki Y, Saga S, Kondoh Y, Taniguchi H, Taki F, Takagi K, Matsuyama M, Suzuki R. Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am J Respir Crit Care Med 1997, 155:43-46.
10. Yassen KA, Galley HF, Webster NR. Matrix metalloproteinase-9 concentrations in critically ill patients. Anaesthesia 2001, 56:729-732. 10.1046/j.1365-2044.2001.02083.x, 11493234.
11. Hoffmann U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, Huhle G, Borggrefe M, Brueckmann M. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis 2006, 38:867-872. 10.1080/00365540600702058, 17008230.
12. Nakamura T, Ebihara I, Shimada N, Shoji H, Koide H. Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment. Am J Med Sci 1998, 316:355-360. 10.1097/00000441-199812000-00001, 9856688.
13. Ricou B, Nicod L, Lacraz S, Welgus HG, Suter PM, Dayer JM. Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996, 154:346-352.
14. Orbe J, Montero I, Rodríguez JA, Beloqui O, Roncal C, Páramo JA. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. J Thromb Haemost 2007, 5:91-97. 10.1111/j.1538-7836.2006.02276.x, 17059420.
15. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodríguez JA, Díez J, Libby P, Páramo JA. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006, 47:1369-1378. 10.1016/j.jacc.2005.10.070, 16580524.
16. Ogata T, Shibamura H, Tromp G, Sinha M, Goddard KA, Sakalihasan N, Limet R, MacKean GL, Arthur C, Sueda T, Land S, Kuivaniemi H. Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. J Vasc Surg 2005, 41:1036-1042. 10.1016/j.jvs.2005.02.020, 1249499, 15944607.
17. Ritter M, Mennerich D, Weith A, Seither P. Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. J Inflamm (Lond) 2005, 2:16. 10.1186/1476-9255-2-16, 1315317, 16316467.
18. Kassim SY, Gharib SA, Mecham BH, Birkland TP, Parks WC, McGuire JK. Individual matrix metalloproteinases control distinct transcriptional responses in airway epithelial cells infected with Pseudomonas aeruginosa. Infect Immun 2007, 75:5640-5650. 10.1128/IAI.00799-07, 2168342, 17923522.
19. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, . International Sepsis Definitions Conference 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003, 29:530-538. International Sepsis Definitions Conference.
20. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
21. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG, . for the Working Group on Sepsis-related Problems of the European Society of Intensive Care Medicine The Sepsis-related Organ Failure Assessment (SOFA) score to describe organ dysfunction/failure. Intensive Care Med 1996, 22:707-710. 10.1007/BF01709751, 8844239, for the Working Group on Sepsis-related Problems of the European Society of Intensive Care Medicine.
22. Marecaux G, Pinsky MR, Dupont E, Kahn RJ, Vincent JL. Blood lactate levels are better prognostic indicators than TNF and IL-6 levels in patients with septic shock. Intensive Care Med 1996, 22:404-408. 10.1007/BF01712155, 8796390.
23. Phua J, Koay ES, Lee KH. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. Shock 2008, 29:328-333. 10.1097/SHK.0b013e318150716b, 18277855.
24. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D, . Sepsis Occurrence in Acutely ill Patients Investigators Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353. 10.1097/01.CCM.0000194725.48928.3A, 16424713, Sepsis Occurrence in Acutely ill Patients Investigators.
25. Mostafa Mtairag E, Chollet-Martin S, Oudghiri M, Laquay N, Jacob MP, Michel JB, Feldman LJ. Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc Res 2001, 49:882-890. 10.1016/S0008-6363(00)00287-X, 11230988.
26. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995, 154:4379-4389.
27. Faveeuw C, Preece G, Ager A. Transendothelial migration of lymphocytes across high endothelial venules into lymph nodes is affected by metalloproteinases. Blood 2001, 98:688-695. 10.1182/blood.V98.3.688, 11468168.
28. Warner RL, Beltran L, Younkin EM, Lewis CS, Weiss SJ, Varani J, Johnson KJ. Role of stromelysin 1 and gelatinase B in experimental acute lung injury. Am J Respir Cell Mol Biol 2001, 24:537-544.
29. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994, 370:555-557. 10.1038/370555a0, 8052310.
30. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998, 161:3340-3346.
31. Ito A, Mukaiyama A, Itoh Y, Nagase H, Thogersen IB, Enghild JJ, Sasaguri Y, Mori Y. Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem 1996, 271:14657-14660. 10.1074/jbc.271.25.14657, 8663297.
32. Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 96:2673-2681.
33. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature 1989, 337:661-663. 10.1038/337661a0, 2537468.
34. Unemori EN, Hibbs MS, Amento EP. Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines. J Clin Invest 1991, 88:1656-1662. 10.1172/JCI115480, 295696, 1658048.
35. Wahl LM, Corcoran ME, Mergenhagen SE, Finbloom DS. Inhibition of phospholipase activity in human monocytes by IFN-gamma blocks endogenous prostaglandin E2-dependent collagenase production. J Immunol 1990, 144:3518-3522.
36. Corcoran ML, Stetler-Stevenson WG, Brown PD, Wahl LM. Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J Biol Chem 1992, 267:515-519.
37. Mertz PM, DeWitt DL, Stetler-Stevenson WG, Wahl LM. Interleukin 10 suppression of monocyte prostaglandin H synthase-2: mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J Biol Chem 1994, 269:21322-21329.
38. Aznaouridis K, Vlachopoulos C, Dima I, Vasiliadou C, Ioakeimidis N, Baou K, Stefanadi E, Stefanadis C. Divergent associations of tissue inhibitors of metalloproteinases-1 and -2 with the prothrombotic/fibrinolytic state. Atherosclerosis 2007, 195:212-215. 10.1016/j.atherosclerosis.2006.12.015, 17222415.
39. Sheu JR, Fong TH, Liu CM, Shen MY, Chen TL, Chang Y, Lu MS, Hsiao G. Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in vivo studies. Br J Pharmacol 2004, 143:193-201. 10.1038/sj.bjp.0705917, 1575278, 15289295.
40. Lee YM, Lee JJ, Shen MY, Hsiao G, Sheu JR. Inhibitory mechanisms of activated matrix metalloproteinase-9 on platelet activation. Eur J Pharmacol 2006, 537:52-58. 10.1016/j.ejphar.2006.03.031, 16624282.
41. Belaaouaj AA, Li A, Wun TC, Welgus HG, Shapiro SD. Matrix metalloproteinases cleave tissue factor pathway inhibitor: effects on coagulation. J Biol Chem 2000, 275:27123-27128.
42. Vanlaere I, Libert C. Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin Microbiol Rev 2009, 22:224-239. 10.1128/CMR.00047-08, 19366913.
43. Dubois B, Starckx S, Pagenstecher A, Oord J, Arnold B, Opdenakker G. Gelatinase B deficiency protects against endotoxin shock. Eur J Immunol 2002, 32:2163-2171. 10.1002/1521-4141(200208)32:8<2163::AID-IMMU2163>3.0.CO;2-Q, 12209628.
44. Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF, . PROWESS Sepsis Study Group Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 2004, 8:R82-R90. 10.1186/cc2459, 420030, 15025782, PROWESS Sepsis Study Group.
45. Esmon CT. Interactions between the innate immune and blood coagulation systems. Trends Immunol 2004, 25:536-542. 10.1016/j.it.2004.08.003, 15364056.
46. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia: a review. Crit Care Med 2006, 34:871-877.
47. Steinberg J, Halter J, Schiller HJ, Dasilva M, Landas S, Gatto LA, Maisi P, Sorsa T, Rajamaki M, Lee HM, Nieman GF. Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J Surg Res 2003, 111:185-195. 10.1016/S0022-4804(03)00089-1, 12850461.
48. Maitra SR, Bhaduri S, Valane PD, Tervahartiala T, Sorsa T, Ramamurthy N. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock 2003, 20:280-285. 10.1097/00024382-200309000-00014, 12923502.